Oxygen Biotherapeutics, Inc. (OTCBB:OXBO) announced that the company has submitted a preliminary Request For Designation (RFD) to the FDA for its first wound care product. The RFD submission is part of a process with the FDA for determining which agency component will have primary jurisdiction for a drug, device or biological product. The product is Oxycyte® Gel in a single-dose packaging delivered as an ointment onto wounds and is protected by a standard bandage.
(more...)